BRIEF-Abbvie Q4 Adjusted EPS USD 2.71 Vs. IBES Estimate USD 2.65

Reuters
Feb 04
BRIEF-Abbvie Q4 Adjusted EPS USD 2.71 Vs. IBES Estimate USD 2.65

Feb 04 (Reuters) - Abbvie Q4 EPS USD 1.02.

  • Q4 revenue USD 16,618 million vs. IBES estimate USD 16,421 million
  • Q4 Global Skyrizi revenue USD 5,006 million
  • Q4 Global Humira revenue USD 1,246 million
  • Q4 Global Rinvoq revenue USD 2,374 million
  • outlook FY adjusted EPS USD 14.37-14.57

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10